冠心病患者血清中MOTS-c水平及其与冠状动脉病变严重程度的关系

孟祥祺; 苑姗姗; 戴红艳; 邢明青; 管军

doi:10.13201/j.issn.1001-1439.2020.03.008

冠心病患者血清中MOTS-c水平及其与冠状动脉病变严重程度的关系

- 1 青岛大学附属青岛市市立医院东院区保健四科(山东青岛, 266000);
- 2 青岛大学附属青岛市市立医院检验科;
- 3 青岛大学附属青岛市市立医院东院区心内科
基金项目:
青岛市民生科技计划项目(No:17-3-3-30-nsh)

详细信息

通讯作者: 管军,E-mail:guanjun@ medmail.com.cn

中图分类号: R541.4

收稿日期: 2019-10-31

修回日期: 2019-12-02

Changes of serum MOTS-c in patients with coronary heart disease and its relationship with degree of coronary artery stenosis

- 1 Department of Healthcare Cardiology, Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao, Shandong, 266000, China;
- 2 Department of Clinical Laboratory, Affiliated Qingdao Municipal Hospital of Qingdao University;
- 3 Department of Cardiology, Affiliated Qingdao Municipal Hospital of Qingdao University

More Information

Corresponding author: GUAN Jun

Received Date: 31 October 2019

Revised Date: 02 December 2019

摘要

摘要: 目的:观察冠心病(CHD)患者血清线粒体衍生肽MOTS-c水平,分析其与冠状动脉(冠脉)病变严重程度的关系,探讨其临床意义。方法:选取行冠脉造影(CAG)的患者60例,其中稳定型心绞痛(SAP)20例(SAP组)、急性心肌梗死(AMI)20例(AMI组),CAG正常者20例(NC组)。采用酶联免疫吸附试验(ELISA)测定血清MOTS-c水平。结果:与NC组比较,SAP组和AMI组患者血清MOTS-c水平均明显降低,且AMI组患者血清MOTS-c水平显著低于SAP组,差异均有统计学意义(P＜0.05)。CHD患者血清MOTS-c水平与Gensini积分呈负相关(r=-0.354,P=0.025)。CHD患者血清MOTS-c与低密度脂蛋白(LDL)水平呈正相关(r=0.411,P=0.008)、与总胆固醇(TC)水平呈正相关(r=0.373,P=0.018),而与年龄、BMI、收缩压、舒张压、尿素氮、肌酐、空腹血糖(FBG)、三酰甘油(TG)、高密度脂蛋白(HDL)、白细胞计数(WBC)、左室射血分数(LVEF)、BNP无显著相关性(P＞0.05)。结论:低水平的MOTS-c可能与CHD的发生、发展相关。MOTS-c可能通过多方面的机制保护内皮及延缓动脉粥样硬化的发生,是CHD的潜在保护因素,或将成为治疗CHD的新靶点。
- 冠心病 /
- 线粒体衍生肽 /
- MOTS-c
Abstract: Objective:To measure the level of serum mitochondrial derived peptide MOTS-c in patients with coronary heart disease(CHD) and analyze the relationship between it and the degree of coronary artery stenosis.Method:The study involved 20 individuals with acute myocardial infarction(AMI),20 individuals with stable angina pectoris(SAP),and 20 healthy individuals as controls.The level of serum MOTS-c was measured by enzyme-linked immunosorbent assay(Elisa).Result:The serum MOTS-c level in SAP group and AMI group was significantly lower than that in NC group,and the serum MOTS-c level in AMI group was significantly lower than that in SAP group(P＜0.05).There was a negative correlation between serum MOTS-c level and Gensini score in patients with CHD(r=-0.354,P=0.025).There was a positive correlation between serum MOTS-c level and LDL-C level(r=0.411,P=0.008) and between serum MOTS-c level and TC level(r=0.373,P=0.018) in CHD patients.There was no significant correlation between serum MOTS-c level with age,BMI,systolic blood pressure,diastolic blood pressure,urea nitrogen,creatinine,FBG,TG,HDL,WBC,LVEF,BNP(P＞0.05).Conclusion:Low levels of MOTS-c may be associated with the occurrence and development of CHD.MOTS-c may protect the endothelium and delay the occurrence and development of atherosclerosis through a variety of mechanisms.It may be a protective factor of cardiovascular system and a new potential target for the treatment of CHD.
- coronary heart disease /
- mitochondrial-derived peptide /
- MOTS-c

HTML全文

参考文献(34)

[1]	Correction to:Heart Disease and Stroke Statistics-2018 Update:A Report From the American Heart Association[J].Circulation,2018,137(12):e493.
[2]	Saghatelian A,Couso JP.Discovery and characterization of smORF-encoded bioactive polypeptides[J].Nat Chem Biol,2015,11(12):909-916.
[3]	Yen K,Lee C,Mehta H,et al.The emerging role of the mitochondrial-derived peptide humanin in stress resistance[J].J Mol Endocrinol,2013,50(1):R11-R19.
[4]	Cobb LJ,Lee C,Xiao J,et al.Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis,insulin sensitivity,and inflammatory markers[J].Aging (Albany NY),2016,8(4):796-809.
[5]	Charununtakorn ST,Shinlapawittayatorn K,Chattipakorn SC,et al.Potential Roles of Humanin on Apoptosis in the Heart[J].Cardiovasc Ther,2016,34(2):107-114.
[6]	Widmer RJ,Flammer AJ,Herrmann J,et al.Circulating humanin levels are associated with preserved coronary endothelial function[J].Am J Physiol Heart Circ Physiol,2013,304(3):H393-H397.
[7]	胡艳清,马建群,冯真真,等.冠心病患者血清抗凋亡多肽Humanin水平变化的临床意义[J].广东医学,2018,39(11):1686-1689.
[8]	Lee C,Zeng J,Drew BG,et al.The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance[J].Cell Metab,2015,21(3):443-454.
[9]	Ramanjaneya M,Bettahi I,Jerobin J,et al.Mitochondrial-Derived Peptides Are Down Regulated in Diabetes Subjects[J].Front Endocrinol (Lausanne),2019,10:331.
[10]	Du C,Zhang C,Wu W,et al.Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance[J].Pediatr Diabetes,2018.
[11]	Fuku N,Pareja-Galeano H,Zempo H,et al.The mitochondrial-derived peptide MOTS-c:a player in exceptional longevity?[J].Aging Cell,2015,14(6):921-933.
[12]	Qin Q,Delrio S,Wan J,et al.Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction[J].Int J Cardiol,2018,254:23-27.
[13]	Montalescot G,Sechtem U,Achenbach S,et al.2013 ESC guidelines on the management of stable coronary artery disease:the Task Force on the management of stable coronary artery disease of the European Society of Cardiology[J].Eur Heart J,2013,34(38):2949-3003.
[14]	Damman P,van 't Hof AW,Ten BJM,et al.2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:comments from the Dutch ACS working group[J].Neth Heart J,2017,25(3):181-185.
[15]	Arslan F,Bongartz L,Ten BJM,et al.2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:comments from the Dutch ACS working group[J].Neth Heart J,2018,26(9):417-421.
[16]	Mancia G,Fagard R,Narkiewicz K,et al.2013 ESH/ESC Guidelines for the management of arterial hypertension:the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J].J Hypertens,2013,31(7):1281-1357.
[17]	Rydén L,Grant PJ,Anker SD,et al.ESC Guidelines on diabetes,pre-diabetes,and cardiovascular diseases developed in collaboration with the EASD:the Task Force on diabetes,pre-diabetes,and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)[J].Eur Heart J,2013,34(39):3035-3087.
[18]	Rampidis GP,Benetos G,Benz DC,et al.A guide for Gensini Score calculation[J].Atherosclerosis,2019,287:181-183.
[19]	Ming W,Lu G,Xin S,et al.Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation[J].Biochem Biophys Res Commun,2016,476(4):412-419.
[20]	Wei R,Ma S,Wang C,et al.Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner[J].Am J Physiol Endocrinol Metab,2016,310(11):E947-E957.
[21]	García-Prieto CF,Pulido-Olmo H,Ruiz-Hurtado G,et al.Mild caloric restriction reduces blood pressure and activates endothelial AMPK-PI3K-Akt-eNOS pathway in obese Zucker rats[J].Vascul Pharmacol,2015,65-66:3-12.
[22]	Kim KH,Son JM,Benayoun BA,et al.The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress[J].Cell Metab,2018,28(3):516-524.e7.
[23]	Mozzini C,Cominacini L,Garbin U,et al.Endoplasmic Reticulum Stress,NRF2 Signalling and Cardiovascular Diseases in a Nutshell[J].Curr Atheroscler Rep,2017,19(8):33.
[24]	Liu C,Gidlund EK,Witasp A,et al.Reduced skeletal muscle expression of mitochondrial-derived peptides humanin and MOTS-c and Nrf2 in chronic kidney disease[J].Am J Physiol Renal Physiol,2019,317(5):F1122-F1131.
[25]	Zhai D,Ye Z,Jiang Y,et al.MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA[J].Mol Immunol,2017,92:151-160.
[26]	刘彦,刘志忠,张俊杰,等.ACS患者血清中IL-6和IL-6R的检测及其临床意义[J].临床心血管病杂志,2015,31(4):389-391.
[27]	Olejarz W,Bryk D,Zapolska-Downar D,et al.Mycophenolic acid attenuates the tumour necrosis factor-α-mediated proinflammatory response in endothelial cells by blocking the MAPK/NF-κB and ROS pathways[J].Eur J Clin Invest,2014,44(1):54-64.
[28]	de Brito FCF.Inhibition of inflammatory pathways promotes an improving effect on endothelial dysfunction:The effects of Longxuetongluo capsule in an experimental model of atherosclerosis[J].Atherosclerosis,2016,255:111-112.
[29]	Otsuka F,Sakakura K,Yahagi K,et al.Has our understanding of calcification in human coronary atherosclerosis progressed?[J].Arterioscler Thromb Vasc Biol,2014,34(4):724-736.
[30]	Wei M,Gan L,Liu Z,et al.Mitochondrial-Derived Peptide MOTS-c Attenuates Vascular Calcification and Secondary Myocardial Remodeling via Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway[J].Cardiorenal Med,2020,10(1):42-50.
[31]	Lee C.Nuclear transcriptional regulation by mitochondrial-encoded MOTS-c[J].Mol Cell Oncol,2019,6(2):1549464.
[32]	朱雁洲,缪海雄,叶椿香,等.糖基化高密度脂蛋白对ApoE-(-/-)小鼠颈动脉粥样硬化斑块稳定性的影响[J].临床心血管病杂志,2018,34(9):928-932.
[33]	Schroeder AP,Falk E.Vulnerable and dangerous coronary plaques[J].Atherosclerosis,1995,118 Suppl:S141-S149.
[34]	Li Q,Lu H,Hu G,et al.Earlier changes in mice after D-galactose treatment were improved by mitochondria derived small peptide MOTS-c[J].Biochem Biophys Res Commun,2019,513(2):439-445.